Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 164 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Papillomavirus (HPV) Vaccines Clear all
Completed Phase 2 Interventional Results available

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

NCT00604175
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent HPV vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 45 Years · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
56
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

NCT00091130
View directory record Official record
Conditions
Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
Interventions
HspE7, placebo, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PreTeenVax Evaluation

NCT03186430
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Comprehensive Vaccine Promotion Package
Behavioral
Lead sponsor
Emory University
Other
Eligibility
11 Years to 12 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
6
States / cities
Canton, Georgia • Duluth, Georgia • Lawrenceville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 22, 2026, 2:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination

NCT02897232
View directory record Official record
Conditions
Papillomavirus Infections, Health Behavior, Attitude of Health Personnel, Human Papilloma Virus, Male
Interventions
Survey
Other
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 22, 2026, 2:43 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*

NCT07339163
View directory record Official record
Conditions
Recurrent Respiratory Papillomatosis (RRP)
Interventions
GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
Biological
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 2:43 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Stories to Prevent (StoP) HPV Cancers

NCT06808776
View directory record Official record
Conditions
Human Papillomavirus Vaccination, Emotions
Interventions
Cancer survivor narrative, Healthy eating tips
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 22, 2026, 2:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

NCT06319963
View directory record Official record
Conditions
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
Drug
Lead sponsor
Theravectys S.A.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 22, 2026, 2:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Feasibility Trial of a Multi-level Media Production and Social Marketing Campaign to Reduce HPV Vaccine Hesitancy

NCT05860725
View directory record Official record
Conditions
Human Papillomavirus Infection, Vaccination Hesitancy
Interventions
PSA Development, HPV vaccination focused social marketing campaign
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 22, 2026, 2:43 PM EDT
Completed No phase listed Observational

Acceptance of Human Papillomavirus Vaccination in Postpartum Women

NCT00730704
View directory record Official record
Conditions
Human Papilloma Virus, HPV, Post Partum
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Not applicable Interventional Results available

Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents

NCT02236273
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Conventional text message reminder, Enhanced text message reminders
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MeFirst: A Tailored Intervention to HPV Vaccine Decision Making

NCT01769560
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
MeFirst Tailored Intervention
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
661 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strengthening Physician Communication About HPV Vaccines

NCT02456077
View directory record Official record
Conditions
HPV Immunization Status
Interventions
Multimodal Vaccine Program
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years and older
Enrollment
93,582 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 22, 2026, 2:43 PM EDT
Active, not recruiting Phase 4 Interventional

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT03023631
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Recombinant Human Papillomavirus Nonavalent Vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

NCT00513526
View directory record Official record
Conditions
Infection, Precancerous Condition
Interventions
Gardasil
Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An HPV Vaccine Provider Intervention in Safety Net Clinics

NCT02808832
View directory record Official record
Conditions
Human Papillomavirus, Uterine Cervical Neoplasms
Interventions
Educational materials
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
9 Years and older
Enrollment
806 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

NCT01190176
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Gynaecological follow-up, Cervarix, Placebo control
Procedure · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
28 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
3
States / cities
Iowa City, Iowa • Wichita, Kansas • Wenatchee, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

NCT00339040
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 12 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
32
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

NCT01424644
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological
Lead sponsor
Novartis
Industry
Eligibility
11 Years to 18 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Fremont, California • Madera, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 22, 2026, 2:43 PM EDT
Recruiting Phase 2Phase 3 Interventional

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

NCT05625633
View directory record Official record
Conditions
Warts
Interventions
Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline
Biological · Other
Lead sponsor
Western Institute for Veterans Research
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

NCT00799825
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
GSK Biological's HPV vaccine GSK580299 (Cervarix™)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
39
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Engaging Clinical Champions to Improve HPV Vaccination

NCT05736718
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Champion Announcement Approach Training, Traditional Announcement Approach Training
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
9 Years to 12 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Usability of HPV Vaccine Reminders

NCT03987490
View directory record Official record
Conditions
Human Papilloma Virus (HPV)
Interventions
Text Message, PostCard, Standard of Care, Motivational Interview
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 22, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

NCT04260126
View directory record Official record
Conditions
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
Interventions
Pembrolizumab (KEYTRUDA®) and PDS0101
Combination Product
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
18
States / cities
Greenbrae, California • San Francisco, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 22, 2026, 2:43 PM EDT
Recruiting Phase 2 Interventional

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

NCT06157151
View directory record Official record
Conditions
Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer
Interventions
PRGN-2009 plus Pembrolizumab
Biological
Lead sponsor
Precigen, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Little Rock, Arkansas • Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 22, 2026, 2:43 PM EDT